What efficacy data support the use of eribulin mesylate in this patient with metastatic TNBC?
The EMBRACE trial was a prospective, randomized study of over 700 women and the treatment recommendation really reflected the real-world care of women. Either your received Halaven or you received treatment of a physician's choice, which was left up to the discretion of the physician, who could choose what they thought that patient would benefit most from. This is based on her comorbidities, based on what she had received previously, and given that choice, eribulin was superior.
Triple Negative Breast Cancer: Case 1
Christine H is a 54-year-old stay-at-home-mother who works part time as a real estate agent. Medical history is notable for hypertension (well controlled) and surgery for aortic aneurysm in 2011
In September 2013, she presented to her PCP with a right breast lump; mammogram showed a large primary breast mass and two enlarged axillary lymph nodes.
At her follow-up in May 2014, the patient showed progression of the right chest wall metastases, and several new liver lesions were detected.
In December of 2014, she presented with increasing fatigue and chest pain on follow up and her CT scan was consistent with progression of the hepatic metastases, with several new lesions also noted in the lungs; her ECOG performance status (PS) at the time was 1.